Angiotensin-converting enzyme inhibitors

Comprehensive Clinical Guide: Angiotensin-Converting Enzyme (ACE) Inhibitors

1. Introduction & Overview

Angiotensin-Converting Enzyme (ACE) inhibitors represent a cornerstone in modern cardiovascular pharmacology. Since the development of captopril in the 1970s, this class of medication has revolutionized the management of hypertension, heart failure, and chronic kidney disease. ACE inhibitors function by inhibiting the enzyme responsible for the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. By modulating the Renin-Angiotensin-Aldosterone System (RAAS), these agents provide significant mortality benefits, organ protection, and hemodynamic stability.

This guide serves as an authoritative clinical resource for healthcare professionals, detailing the pharmacodynamic, pharmacokinetic, and therapeutic profiles of ACE inhibitors.

2. Mechanism of Action (MOA)

The efficacy of ACE inhibitors is rooted in their targeted interference with the RAAS pathway.

The RAAS Cascade

1. Renin Release: Triggered by decreased renal perfusion or sympathetic stimulation.
2. Angiotensinogen Conversion: Renin converts angiotensinogen to angiotensin I.
3. ACE Conversion: The Angiotensin-Converting Enzyme (found primarily in pulmonary endothelium) converts angiotensin I to angiotensin II (Ang II).

Pharmacological Inhibition

ACE inhibitors competitively bind to the active site of the ACE enzyme, preventing the conversion of Ang I to Ang II. The clinical consequences of this inhibition are profound:

• Vasodilation: Reduced Ang II levels lead to systemic arteriolar and venous vasodilation, decreasing systemic vascular resistance (SVR) and afterload.
• Aldosterone Suppression: Decreased Ang II reduces adrenal secretion of aldosterone, promoting sodium and water excretion and potassium retention.
• Kinins: ACE is also responsible for the degradation of bradykinin. By inhibiting ACE, these drugs increase bradykinin levels, which stimulates nitric oxide and prostacyclin production, further contributing to vasodilation.

3. Pharmacokinetics

While all ACE inhibitors share a common mechanism, their pharmacokinetic properties differ significantly, influencing dosing frequency and metabolic clearance.

• Prodrugs: Agents like Enalapril and Ramipril are prodrugs that require hepatic hydrolysis to their active forms (Enalaprilat, Ramiprilat).
• Renal Excretion: Most ACE inhibitors are eliminated via the kidneys, necessitating dose adjustments in patients with renal impairment (CrCl < 30 mL/min).

4. Clinical Indications & Usage

ACE inhibitors are indicated for a broad spectrum of cardiovascular and renal pathologies.

Primary Indications

• Hypertension: First-line therapy, particularly in patients with comorbid diabetes or proteinuria.
• Heart Failure (HFrEF): Proven to reduce mortality and hospitalizations in patients with reduced ejection fraction.
• Post-Myocardial Infarction: Initiation within 24 hours of an acute MI to prevent ventricular remodeling and improve survival.
• Chronic Kidney Disease (CKD): Renoprotective effects in patients with diabetic nephropathy by reducing intraglomerular pressure.

General Dosage Guidelines

• Initiation: Always "start low and go slow" to prevent first-dose hypotension, especially in volume-depleted patients or those on diuretics.
• Titration: Dose increases should typically occur at 1–2 week intervals based on blood pressure response and serum creatinine/potassium levels.

5. Risks, Side Effects, and Contraindications

Common Adverse Effects

• Dry Cough: Occurs in 5–20% of patients due to bradykinin accumulation in the lungs. If persistent, patients should be switched to an Angiotensin II Receptor Blocker (ARB).
• Hyperkalemia: Due to reduced aldosterone secretion. Requires monitoring of serum potassium, particularly in patients on potassium-sparing diuretics or NSAIDs.
• First-dose Hypotension: Common in patients with high baseline renin activity (e.g., those on aggressive diuretic therapy).

Serious Adverse Effects

• Angioedema: A rare but life-threatening swelling of the face, tongue, and glottis. It can occur at any time, even years after therapy initiation. Immediate discontinuation is required.
• Acute Kidney Injury (AKI): ACE inhibitors can precipitate renal failure in patients with bilateral renal artery stenosis.

Contraindications

1. Pregnancy: Categorized as FDA Category D (2nd/3rd trimester). Risk of fetal renal dysgenesis and oligohydramnios.
2. History of Angioedema: Any patient with a prior history of angioedema (hereditary or drug-induced) should not receive an ACE inhibitor.
3. Bilateral Renal Artery Stenosis: Can lead to a precipitous drop in GFR.
4. Concomitant Aliskiren Use: In patients with diabetes.

6. Drug Interactions

The clinical utility of ACE inhibitors is often complicated by polypharmacy.

• NSAIDs: Reduce the antihypertensive effect by inhibiting prostaglandin-mediated vasodilation; increases risk of AKI.
• Potassium Supplements/K-sparing Diuretics: Dramatically increases the risk of life-threatening hyperkalemia.
• Lithium: ACE inhibitors can decrease lithium clearance, leading to lithium toxicity.
• Diuretics: May cause an exaggerated hypotensive response.

7. Pregnancy and Lactation

• Pregnancy: ACE inhibitors are strictly contraindicated during pregnancy. They interfere with fetal renal development, leading to fetal hypotension, renal failure, and neonatal death. If pregnancy is detected, the medication must be discontinued immediately.
• Lactation: While trace amounts may pass into breast milk, the clinical significance is generally considered low. However, alternative agents (e.g., Labetalol) are usually preferred in breastfeeding mothers.

8. Overdose Management

Overdose of ACE inhibitors typically manifests as severe hypotension and electrolyte imbalances.

1. Supportive Care: Place the patient in a supine position with legs elevated (Trendelenburg).
2. Volume Expansion: Administer isotonic saline (0.9% NaCl) to address potential hypovolemia.
3. Vasopressors: If hypotension is refractory to fluids, consider norepinephrine or phenylephrine.
4. Monitoring: Continuous ECG monitoring for arrhythmias secondary to hyperkalemia.
5. Hemodialysis: While ACE inhibitors are dialyzable, it is rarely required unless the overdose involves co-ingestants or severe renal failure.

9. Frequently Asked Questions (FAQ)

1. Why do patients develop a dry cough on ACE inhibitors?

The cough is caused by the inhibition of the enzyme kininase II, which leads to the accumulation of bradykinin in the respiratory tract. This is a class effect and not an allergic reaction.

2. Can I switch from an ACE inhibitor to an ARB if I have a cough?

Yes. ARBs (Angiotensin Receptor Blockers) do not inhibit the breakdown of bradykinin and are the standard alternative for patients who cannot tolerate ACE inhibitors due to cough.

3. How soon should I monitor kidney function after starting an ACE inhibitor?

It is standard clinical practice to check serum creatinine and potassium levels 1–2 weeks after initiation or dose escalation.

4. Is a mild increase in creatinine normal after starting an ACE inhibitor?

A rise in serum creatinine of up to 30% from baseline is often considered acceptable, as it reflects the stabilization of intraglomerular pressure. Increases beyond this warrant investigation for renal artery stenosis.

5. Why are ACE inhibitors contraindicated in pregnancy?

They cause fetal hypotension and renal hypoperfusion, which can result in Potter’s sequence (hypoplasia of the lungs, skeletal abnormalities, and renal failure).

6. Can ACE inhibitors be used in patients with Type 1 Diabetes?

Yes, they are highly recommended as they provide renoprotection by slowing the progression of diabetic nephropathy, independent of blood pressure lowering.

7. What is the difference between ACE inhibitors and ARBs?

ACE inhibitors block the production of Angiotensin II, while ARBs block the binding of Angiotensin II to the AT1 receptor. ARBs do not affect bradykinin levels, hence the lower incidence of cough.

8. What should I do if my patient develops angioedema?

Discontinue the medication immediately, secure the airway, and administer epinephrine, corticosteroids, and antihistamines as needed. Never re-challenge the patient with an ACE inhibitor.

9. Are all ACE inhibitors dosed once daily?

No. Captopril has a short half-life and requires TID dosing, whereas Lisinopril, Ramipril, and others are formulated for once-daily dosing.

10. Does food affect the absorption of ACE inhibitors?

For most, food does not significantly affect absorption, but patients should be consistent in how they take their medication to ensure stable plasma concentrations.

10. Conclusion

ACE inhibitors remain an indispensable tool in the clinician’s armamentarium. Their ability to manage hypertension while providing profound benefits in heart failure and diabetic nephropathy makes them a first-line choice for millions of patients. By understanding the nuances of their pharmacokinetics, potential for drug interactions, and the critical importance of monitoring for adverse effects like angioedema and hyperkalemia, healthcare providers can optimize patient outcomes and minimize risks.

Disclaimer: This guide is for educational purposes only and does not constitute medical advice. Always consult local clinical guidelines and institutional protocols when prescribing pharmacotherapy.